# Effect of Sublingual Fentanyl on Breathlessness in COPD

> **NCT04004117** · PHASE2,PHASE3 · TERMINATED · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 40 (actual)

## Conditions studied

- Copd

## Interventions

- **DRUG:** Fentanyl citrate solution sublingual
- **DRUG:** Placebo oral liquid

## Key facts

- **NCT ID:** NCT04004117
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2026-02-04
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Clinical trial discontinued for reason pertaining to lack of efficacy.
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04004117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04004117, "Effect of Sublingual Fentanyl on Breathlessness in COPD". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04004117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*